Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib in Triple Negative Breast Cancer
NCT03911453Phase 1Completed
- Sponsor
- University of Arizona
- Start
- Apr 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rucaparib in triple negative breast cancer (TNBC), sponsored by University of Arizona. Primary endpoint: Expression of PD-L1 by IHC at 6 months. Started Apr 2019; status: completed.
02
Drugs
rucaparib
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03911453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03911453.